News | Molecular Imaging | June 13, 2017

SNMMI Elects Bennett S. Greenspan, M.D., MS, FACNM, FACR, as President

During 2017 annual meeting new officers elected for 2017-2018

Bennett S. Greenspan, M.D.

Bennett S. Greenspan, M.D.

Bennett S. Greenspan, M.D., MS, FACNM, FACR, professor of radiology at the Medical College of Georgia, Augusta University, in Augusta, Ga., has assumed office as 2017-18 president of the Society of Nuclear Medicine and Molecular Imaging (SNMMI). SNMMI introduced a new slate of officers during its 2017 Annual Meeting, June 10-14, in Denver, Colorado.      

“As SNMMI President, in the year ahead I will focus on the new Value Initiative and strategic plan, which emphasize quality of practice; research and development; strengthening education and the workforce pipeline; advocacy for molecular imaging, nuclear medicine, and targeted therapy procedures that improve patient care; and outreach that explains the field’s critical role in modern medicine,” Greenspan said.

With the focus on quality and value, Greenspan will continue SNMMI’s development of appropriate use criteria (AUC) and updating procedure guidelines for many nuclear medicine imaging procedures. He will also work on establishing more efficient and timely approval of novel radiotracers. His ultimate focus is on improving patients’ lives. “These improvements can lead to more appropriate utilization of diagnostic nuclear medicine exams and also radionuclide therapy, which will benefit patients,” he explained. “These goals can be facilitated by working closely with other societies and governmental agencies.”

Prior to his position as professor of radiology at the Medical College of Georgia at Augusta University, Greenspan worked at the Mount Sinai School of Medicine in New York, N.Y.; University of Rochester in Rochester, N.Y.; University of Missouri-Columbia; and Washington University in St. Louis, MO.  Greenspan is devoted to teaching clinical nuclear medicine, as well as nuclear medicine physics and radiation safety, to nuclear medicine and radiology residents. He is a member of three committees of the American Association of Physicists in Medicine (AAPM): one on teaching medical physics to radiology residents, one on the development of the medical physics curriculum for radiology residents, and one on the physics of nuclear medicine.

Consistent with his keen interest in ensuring that nuclear medicine delivers the highest quality of care, Greenspan serves on the SNMMI Quality and Evidence Committee, is a reviewer for quality assurance in nuclear medicine for the American College of Radiology (ACR), and was a member of the PET Quality and Reporting Task Force of SNMMI’s PET Center of Excellence. He is a co-author of the paper “Reporting Guidance for Oncologic FDG PET/CT Imaging,” published in the May 2013 issue of The Journal of Nuclear Medicine.

Greenspan holds a Master of Science degree in medical physics from the University of California, Los Angeles, and earned his medical degree at the University of Illinois in Chicago. He served residencies in diagnostic radiology and nuclear medicine and is certified in diagnostic radiology and nuclear radiology by the American Board of Radiology (ABR) and in nuclear medicine by the American Board of Nuclear Medicine (ABNM).

Greenspan’s research and scholarly interests include PET/CT imaging in oncology, especially using PET imaging to further characterize malignancies; evaluation of osteoporosis; and the effects of low-level radiation. He has been a co-investigator on 11 grants.

Greenspan is a Fellow of the ACR and the American College of Nuclear Medicine (ACNM). He currently serves on the boards of the American Board of Science in Nuclear Medicine and the Nuclear Medicine Technology Certification Board. He is past chair of the SNMMI Committee on Councils and served as co-chair of the ACR Nuclear Medicine Procedure Guidelines Committee.

He has been president of the American College of Nuclear Physicians (ACNP), the Missouri Radiological Society, the SNMMI Academic Council (twice), the Missouri Valley Chapter of SNMMI (twice) and the American Board of Science in Nuclear Medicine. At SNMMI, he has served on the Board of Directors and on the boards of the Academic Council, Advanced Associate Council, Nuclear Oncology Council and Computer and Instrumentation Council. Greenspan has also served on the boards of the ACNM, the Intersocietal Commission for the Accreditation of Computed Tomography Laboratories (now the Intersocietal Accreditation Commission – IAC), and the Academy of Radiology Research, as well as on the executive councils of the ACNP and the ACR Intersociety Summer Conference. Greenspan continues to serve on numerous committees and task forces of the SNMMI, ACNM, ACR, Radiological Society of North America, Association of University Radiologists, AAPM and NMTCB. He has also been an ABR oral board examiner. 

Other SNMMI officers elected for 2017-18 are Satoshi Minoshima, M.D., Ph.D., Salt Lake City, Utah, as president-elect, and Vasken Dilsizian, M.D., Baltimore, Maryland, as vice president-elect. SNMMI Technologist Section officers for 2017-18 are Kathleen Krisak, CNMT, FSNMMI-TS, Granby, Mass., as president, and Norman Bolus, MSPH, CNMT, FSNMMI-TS, Birmingham, Alabama, as president-elect.

 

For more information: www.snmmi.org

Related Content

Study Demonstrates First Human Application of Novel PET Tracer for Prostate Cancer

Transaxial 11Csarcosine hybrid PET/CT showed a (triangulated) adenocarcinoma in the transition zone of the anterior right prostate gland on PET (A), CT (B), and a separately obtained T2?weighted MR sequence (C) with resulting PET/MRI registration (D). Image courtesy of M. Piert et al., University of Michigan, Ann Arbor, Mich.

News | Radiopharmaceuticals and Tracers | August 16, 2017
In the featured translational article in the August issue of The Journal of Nuclear Medicine, researchers at the...
PET/CT Tracer Identifies Vulnerable Lesions in Non-Small Cell Lung Cancer Patients

Example of a patient with an upper left lung NSCLC: A: FDG; B: FDG PET/CT; C: Planning radiotherapy based on FDG (66Gy) with BTVm (GTV), CTV and PTV; D: PET FMISO E: FMISO PET/CT; F: boost based on the FMISO PET (76Gy) with BTVh (biological hypoxic target volume) and PTV boost. Credit: QuantIF – LITIS EA 4108 – FR CNRS 3638, Henri Becquerel Cancer Center, Rouen, France

News | PET-CT | July 14, 2017
July 14, 2017 — Fluorine-18 (18F)-fluoromisonidazole (FMISO) is a positron emission tomography (PET)...
Novel PET Tracer Detects Small Blood Clots

PET images (MIP 0-60 min) of three Cynomolgus monkeys. Strong signals are detected at the sites where inserted catheters had roughened surfaces. Almost no other background signal is visible. Only accumulation in the gallbladder becomes visible at the bottom of the image. Credit: Piramal Imaging GmbH, Berlin Germany.

News | PET Imaging | July 07, 2017
July 7, 2017 — Blood clots in veins a
Sponsored Content | Videos | Clinical Decision Support | June 29, 2017
Rami Doukky, M.D., system chair, Division of Cardiology, professor of medicine, Cook County Health and Hospitals Syst
Diagnostic Radiation Exposure Safe for Children, Experts State
News | Pediatric Imaging | June 21, 2017
In an article published in the June 2017 issue of The Journal of Nuclear Medicine, researchers assert that exposure to...
Dual-Agent PET/MR With Time of Flight Detects More Cancer

Tc-99m MDP bone scan (left) is negative for osseous lesions. NaF/FDG PET/MRI (right and second slide) confirms absence of bone metastases, but shows liver metastases. Image courtesy of Stanford University.

News | PET-MRI | June 20, 2017
Simultaneous injections of the radiopharmaceuticals fluorine-18 fluorodeoxyglucose (18F-FDG) and 18F-sodium fluoride (...
Combined Optical and Molecular Imaging Could Guide Breast-Conserving Surgery

WLE specimen from a patient with a grade 3, ER-/HER2-, no special type (NST) carcinoma. (A) Cerenkov image; (B) Grey-scale photographic image overlaid with Cerenkov signal. An increased signal from the tumor is visible (white arrows); mean radiance is 871 ± 131 photons/s/cm2/sr, mean TBR is 3.22. Both surgeons measured the posterior margin (outlined in blue) as 2 mm (small arrow); a cavity shaving would have been performed if the image had been available intraoperatively. The medial margin (outlined in green) measured >5 mm by both surgeons. Pathology ink prevented assessing the lateral margin; a phosphorescent signal is visible (open arrows). (C) Specimen radiography image. The absence of one surgical clip to mark the anterior margin, and the odd position of the superior margin clip (white arrow) prevented reliable margin assessment. (D) Combined histopathology image from two adjacent pathology slides on which the posterior margin (bottom of image) and part of the primary tumor are visible (open arrows). The distance from the posterior margin measured 3 mm microscopically (double arrow). The medial margin is > 5 mm (not present in image). Credit: A. D. Purushotham, M.D., King’s College London, UK

News | Nuclear Imaging | June 20, 2017
June 20, 2017 — Breast-conserving surgery (BCS) is the primary treatment for early-stage...
A 77-year-old male with recurrent lymph node and pulmonary metastases detected by Ga-68 PSMA PET/CT but not by conventional imaging

A 77-year-old male with recurrent lymph node and pulmonary metastases detected by Ga-68 PSMA PET/CT but not by conventional imaging. Graphic courtesy of the Department of Nuclear Medicine, Royal North Shore Hospital, Sydney

News | Prostate Cancer | June 15, 2017
An estimated one in seven American men will be affected by prostate cancer in their lifetime. Prostate-specific...
Overlay Init